Rapid Pathogen Screening
Sarasota
About Rapid Pathogen Screening
Founded in 2004, Rapid Pathogen Screening, Inc. (RPS®) is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment. For more information on RPS or its products, visit RPSdetectors.com.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $56.0M
- Funding stage: M&A
- Last round: Debt Financing (Oct 2014)
- Website: rpsdetectors.com
- Phone: +1 941 556 1850
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/rapid-pathogen-screening-2418593 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.